

FOI 3619

10th March 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients have been diagnosed with Prostate Cancer (ICD-10 code = C61) in the past 12 months?

	Number of Patients
Prostate Cancer	

Response:

	Number of Patients
Prostate Cancer	379 prostate cancer patients were diagnosed calendar year 2025.

Q2. How many patients have been diagnosed with Localised Prostate Cancer (meaning the cancer is contained within the prostate and has not spread elsewhere, T1 or T2 on the TNM staging scale) in the past 12 months?

	Number of Patients
Localised Prostate Cancer	

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of all individual patient note reviews. Even the CPG data will require review of each patients individual MDM outcome, just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q2b. How many patients with Prostate Cancer (C61) do you have in the following risk categories based on the Cambridge Prognostic Group (CPG)

Low risk prostate cancer - CPG 1

- Grade Group 1 (Gleason score of 6)
- and a PSA level less than 10 ng/ml
- and a T stage of 1 or 2

Medium risk prostate cancer CPG 2 and CPG 3

- Grade Group 2 or 3 (Gleason score of 7)
- or a PSA level between 10 and 20 ng/ml
- and a T stage of 1 or 2

High risk prostate cancer - CPG 4 and CPG 5.

- Grade Group 4 (previously called a Gleason score of 8 - 10)
- PSA level higher than 20 ng/ml
- T stage of 3 or 4

Patient Risk Group	Number of Patients
Low risk prostate cancer - CPG 1	
Medium risk prostate cancer CPG 2 and CPG 3	
High risk prostate cancer - CPG 4 and CPG 5	

Response: Please see response to Question 2 as above.

Q3. How many patients with Localised Prostate Cancer are currently under Active Surveillance as recommended in NHS England Guidelines for the Management of Prostate Cancer?

	Number of Patients
Localised Prostate Cancer Active Surveillance	

Response: Please see response to Question 2.

Q4. How many Prostatectomy procedures have been carried out in your Trust or organisation in the past 12- months?

Procedure Code	Procedure Description	Number of Procedures
M61	Total excision of prostate	
M62	Other excision of prostate	
M64	Endoscopic excision of prostate	

Response: Please refer to attachment 1.

Q4b. How many Prostatectomy procedures have been carried out on patient with High-risk prostate cancer - CPG 4 and CPG 5 in your Trust or organisation in the past 12-months?

Procedure Code	Procedure Description	Number of Procedures
M61	Total excision of prostate	
M62	Other excision of prostate	
M64	Endoscopic excision of prostate	

Response: Please refer to attachment 2.

Q5. How many patients with Prostate Cancer (ICD-10 code = C61) are currently being treated with the following hormone therapies?

Hormone therapy name	Number of Patients
5.1 Leuprorelin	
5.2 Goserelin acetate	
5.3 Busereli	
5.4 Triptorelin	
5.5 Degarelix	
5.6 Relugolix	
5.7 Bicalutamide	
5.8 Flutamide	
5.9 Cyproterone acetate	

Response: Please see response to Question 2.

Q6. How many patients with Localised Prostate Cancer are currently being treated with the following hormone therapies?

Hormone therapy name	Number of Patients
6.1 Leuprorelin	
6.2 Goserelin acetate	
6.3 Buserelin	
6.4 Triptorelin	
6.5 Degarelix	

6.6 Relugolix	
6.7 Bicalutamide	
6.8 Flutamide	
6.9 Cyproterone acetate	

Response: Please see response to Question 2.

Q7. How many External Beam Radiotherapy (EBRT) procedures have been carried out on patients with Prostate Cancer (C61) in the past 12-months?

Procedure Code	Procedure Description	Number of Procedures
X64.4	Delivery of a fraction of external beam radiotherapy	
O44.8	Other specified external beam radiotherapy	
O44.9	Unspecified external beam radiotherapy	

Response: Please see response to Question 2.

Q8. How many Brachytherapy procedures have been carried out on patients with Prostate Cancer in the past 12-months?

Procedure Code	Procedure Description	Number of Procedures
M71.2	Implantation of radioactive substance into prostate	
Y35.4	Introduction of radioactive substance into organ for brachytherapy	
Y36	Other introduction of radioactive material	
X65.2	Intracavitary Brachytherapy	

Response: Please see response to Question 2.

Email: Foi.Team@Southerntrust.hscni.net